Biotech
NDude Labs invests in nutraceutical ingredients firm Nutriventia
The investment will help Nutriventia strengthen its research and development pipeline, expand its global commercial presence and scale its proprietary ingredient technology platform, the company said in a statement.
MSD inaugurates 2.5 lakh sq ft tech centre in Hyderabad
Global biopharmaceutical company MSD has opened a new technology centre in Hyderabad. This facility will enhance the company's digital, data, and AI capabilities. The centre supports MSD's global Human Health business operations. Telangana's minister highlighted Hyderabad's evolving life sciences ecosystem.
Govt eases loan licence requirement for 'outsourced' sterilisation of medical gear
Medical device makers now avoid loan licenses for outsourced sterilization services. This change simplifies business while industry leaders express concerns about new labeling rules. Printing sterilizer license numbers on device labels may hinder export flexibility and cause shipment delays. Manufacturers worry about losing the ability to choose the fastest available sterilization facility. The government also recognized the European Union for clinical investigation waivers.
Danish firm Novonesis to roll out ₹3,000 crore Maharashtra investment over 2-3 years
Novonesis will likely expand its Patalganga manufacturing facility with this capital. New yeast technologies can reduce fermentation time and improve production yields. Biological solutions are also being introduced to boost sugarcane output in Karnataka. Regulatory challenges remain a key hurdle for wider adoption of these bio-solutions.
Mankind Pharma inks in-licensing pact with China's Chongqing Chenan Biopharmaceutical
Mankind Pharma has secured an exclusive agreement with Chongqing Chenan Biopharmaceutical. This partnership focuses on commercialising two insulin analogues for diabetes care. The deal will enhance Mankind Pharma's injectable diabetes segment offerings. These new products will strengthen the company's comprehensive patient portfolio.
Lord’s Mark Industries announces license for biomescan analytics platform
Lord's Mark Industries has obtained a license for its groundbreaking Biomescan Analytics Platform, which specializes in assessing the gut microbiome to deliver customized health insights. With ambitious plans to set up 3,000 health centers across India in the next three years, the initiative aims to offer gut assessments and personalized nutritional advice, promoting proactive health and enhancing long-term wellness outcomes.
Thermo Fisher finds India the perfect lab; lab equipment maker steps up investments as drug companies focus on innovation
Thermo Fisher Scientific is amplifying its investment footprint in India, driven by the strong anticipated growth in the biosimilars and innovative medicines sectors. With projections indicating a substantial rise in India's biosimilars exports by 2030, local pharmaceutical companies are pivoting towards advanced biologics and research initiatives. To foster scientific talent, Thermo Fisher has also established a bioprocess center in Hyderabad for comprehensive training.
NITI Aayog roadmap targets USD 691 bn bioeconomy by 2035; Jitendra Singh says India ready to lead biotech revolution
India's bioeconomy can reach USD 691 billion by 2035, creating millions of high-value jobs. The nation aims to become a top global biotechnology power, driving future growth. A roadmap proposes six National BioMissions and a significant growth fund for development. Talent development, including engineering biology courses, is deemed critical for this ecosystem. This expansion will address national goals like health and food security.
Jitendra Singh releases Rs 1,500 crore under third phase of Biomedical Research Career Programme
Union Minister Jitendra Singh released fifteen hundred crore rupees for the Biomedical Research Career Programme. This funding supports outstanding biomedical researchers and promotes collaborative research initiatives. The program, initiated in two thousand eight, has supported over five hundred researchers. It has also strengthened research across more than two hundred institutions nationwide.
OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars
OneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSource providing integrated manufacturing capabilities for biosimilars. The partnership aims to expand access to high-quality, affordable biologics for patients globally. Formycon AG CEO stated this strengthens their supply capabilities with a quality-focused partner. Both companies aim to broaden sustainable global access to life-changing biosimilar therapies.
Must Watch
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosis
A gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Since the NGS test can be beyond the reach of many, a unique collaboration called LuNGS Alliance is making it free for lung cancer patients in India, offering a glimpse of how medical breakthroughs can be made accessible and affordable.
Societe General, Prudential, others buy 3 per cent stake in Anthem Biosciences for Rs 1,275 cr
Global investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a 3 percent stake in Anthem Biosciences. The deal, valued at Rs 1,275 crore, saw promoter Aruna Ganesh exit the company. This significant transaction reshapes the promoter's holding in the integrated Contract Research, Development and Manufacturing Organisation.
GVK-backed Oval Fertility launched in Hyderabad, eyes share in India's growing IVF market
GVK family-backed Oval Fertility has launched its first premium IVF center in Hyderabad, leveraging advanced embryo monitoring technology. Co-founded by US fertility specialist Dr. Brian Levine and Veena Reddy, the venture aims to redefine fertility care with a blend of science, technology, and personalized patient experience. The clinic, priced at Rs 4.
Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow Tucker
Eli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant contributor to the condition. Unlike previous therapies that merely alleviate symptoms, this innovative medication aims to modify the disease itself.
Biocon shifts focus to margins, capacity utilisation after expansion phase
Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in global capabilities. The company reported a 13% revenue increase for FY26, though net profit saw a substantial decline. Biocon is also prioritizing sustainable, profitable growth and exploring in-licensing opportunities for its biosimilars portfolio.
Kiran Mazumdar-Shaw picks niece Claire as successor at Biocon
Biocon's founder Kiran Mazumdar-Shaw has made a groundbreaking announcement, pledging her niece Claire Mazumdar as her heir apparent. The transition plan is designed for a slow handover while Mazumdar-Shaw remains at the helm.
